A Double-Blind Comparison of Buspirone, Clobazam, and Placebo in Patients with Anxiety Treated in a General Practice Setting

Böhm, Claus; Placchi, M.; Stallone, Frank; Gammans, Richard E.; Alms, Donald R.; Shrotriya, Rajesh C.; Robinson, Donald S.

doi:10.1097/00004714-199006001-00008

Cited by 31 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rickels et al 1988;Ansseau et al 1990;Enkelmann 1991). However, a similar onset of anxiolytic activity during the Þrst week of treatment for buspirone when compared with benzodiazepines has been demonstrated in other studies (Pecknold et al 1989;Böhm et al 1990;Strand et al 1990).…”

Section: Introductionmentioning

confidence: 66%

“…By contrast, the benzodiazepines have been observed to achieve a more rapid improvement of anxiety (Rickels et al 1988;Enkelmann 1991). In other studies, the onset of anxiolytic activity was comparable between buspirone and benzodiazepines (Pecknold et al 1989;Böhm et al 1990;Strand et al 1990). In our study, buspirone was not able to catch up to lorazepam as long as active drugs were administered.…”

Section: Discussionmentioning

confidence: 97%

“…Double-blind treatment studies in patients with generalized anxiety disorder (GAD) generally revealed that buspirone is equally e¤ective in anxiety disorders compared to the benzodiazepines diazepam (Goldberg and Finnerty 1979;Rickels et al 1982;Moring et al 1989), lorazepam (Cohn and Wilcox 1986;Petracca et al 1990), oxazepam (Ansseau et al 1990;Strand et al 1990), alprazolam (Cohn and Wilcox 1986;Enkelman 1991), clobazam (Böhm et al 1990), and clorazepate (Goldberg and Finnerty 1982;Rickels et al 1988). In addition, buspirone seems to avoid the well-known side e¤ects of benzodiazepines : it does not cause impairment of memory, cognitive performance or driving skills in clinical doses Moskowitz and Smiley 1982;Erwin et al 1986).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients

Laakmann¹,

Schüle²,

Lorkowski³

et al. 1998

Psychopharmacology

View full text Add to dashboard Cite

In this double-blind, placebo-controlled 10-week trial, the anxiolytic properties of the nonbenzodiazepine buspirone were compared with the benzodiazepine lorazepam and placebo in 125 outpatients with generalized anxiety disorder according to DSM-III. After a 3-to 7-day wash-out period, patients were allocated at random to receive orally 3 × 5 mg buspirone (n = 58), 3 × 1 mg lorazepam (n = 57), or placebo (n = 10) over a 4-week period. The study also comprised a 2-week taper period and a 4-week placebocontrol period to assess the stability of clinical improvement. The patient´s clinical state was estimated on entry and at weekly intervals by general practitioners using the Hamilton Rating Scale for Anxiety (HAM-A) and Clinical Global Impression (CGI) assessment and by a self-rating scale (State Trait Anxiety Inventory X2 = STAI-X2). Lorazepam treatment resulted in descriptively, but not signiÞcantly, greater improvement on the Hamilton Rating Scale for Anxiety during the whole treatment (week 0 4) and taper period (week 5, 6) than did buspirone. After treatment with active drugs had been discontinued, the 4-week placebo control period showed buspirone-treated patients to display a stability of clinical improvement, while the symptoms of lorazepam-treated patients worsened at week 710. Both buspirone and lorazepam were more e¦cacious in reducing anxiety symptoms than placebo during the treatment and taper period; however, in contrast to the active drugs (buspirone, lorazepam), patients of the placebo group showed further clinical improvement during the control period, especially in the HAM-A score, so di¤erences between placebo and active drugs became smaller at the end of the study.

show abstract

Section: Introductionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients

Laakmann¹,

Schüle²,

Lorkowski³

et al. 1998

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The alpha decrease also indicates a vigilance decrease, which is less pronounced. The hemisphere-specific changes (increase in source strength over the left temporal, parietal and superior frontal region, followed by a decrease over the right or bilateral prefrontal, temporal pole and occipital region) show a remarkable similarity to the LORETA changes described after 20 mg buspirone [23] , a 5-HT1A partial agonist successfully applied in the treatment of anxiety [24][25][26][27][28] . 20 and 40 mg ABIO-08/01 also induced this dissociative vigilance type in the 1st hour after acute administration, but in the 6th hour these doses caused a less-pronounced decrease in alpha and beta activity and thus less sedative effects than 10 mg less.…”

Section: Discussionmentioning

confidence: 82%

Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study on the Pharmacodynamics of ABIO-08/01, a New CNS Drug with Potential Anxiolytic Activity

Saletu¹,

Anderer²,

Wolzt

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

Effects of ABIO-08/01, a new potentially anxiolytic isoxazoline, on regional electrical brain generators were investigated by 3-dimensional EEG tomography. In a double- blind, placebo-controlled, multiple-ascending-dose study, 16 healthy males (30.2 ± 5.7 years) received 3 oral drug doses (10, 20, 40 mg) and placebo for 7 days (8-day wash-out) in a randomized non-balanced design for phase-1 studies. A 3-min vigilance-controlled (V) EEG, a 4-min resting (R) EEG with eyes closed, a 1-min eyes-open (EO) EEG and psychometric tests were performed 0, 1 and 6 h after taking the drug on days 1 and 5. Low-resolution brain electromagnetic tomography (LORETA) was computed from the spectrally analyzed EEG data, and differences between drug and placebo were displayed as statistical parametric maps. Data were registered to the Talairach-Tournoux Human Brain Atlas available as a digitized MRI. An overall omnibus significance test followed by a voxel-by-voxel t test demonstrated significant regional EEG changes after ABIO-08/01 versus placebo, dependent on recording condition, dose and time. While in the EO-EEG specifically the lowest dose of ABIO-08/01 induced pronounced sedative effects (delta/theta and beta increase) 1 h after acute and slightly less so after superimposed administration, in the 6th hour a decrease in alpha and beta activity signaled less sedative and more relaxant action. In the V-EEG these changes were less pronounced, in the R-EEG partly opposite. Hemisphere-specific changes were observed, suggesting increases in LORETA power over the left temporal, parietal, superior frontal regions and decreases over the right prefrontal, temporal pole and occipital regions. These LORETA changes are discussed in the light of neuroimaging findings on anxiety and anxiolytics.

show abstract

“…Clinical evidence that serotonin may be involved in generalized anxiety disorder (GAD) is mainly derived from studies with selective 5-HTIA agonists, such as buspirone, which have beneficial effects in this condition (Rickels et al, 1982;Schuckit, 1984;Jacobson et al, 1985;Feighner, 1987;Olajide and Lader, 1987;Bohm et al, 1990;Strand et al, 1990). As anxiolytic effects are apparent only after repeated administration, it is thought that adaptive changes in serotonin receptors are required for clinically relevant effects.…”

Section: Selective Serotonin Agonistsmentioning

confidence: 99%

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review

Boer¹,

Westenberg²

1995

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

The recognition that antidepressants are effective in panic and anxiety disorders had led to the evaluation of drugs selective for serotonin uptake in an attempt to dissect the neurotransmitters responsible for panic disorder. Fluvoxamine is the best studied of the selective serotonin reuptake inhibitors (SSRIs) and recent double-blind studies have confirmed earlier findings showing a reduced number and duration of panic attacks. In addition, fluvoxamine attenuates the 'accessory symptoms' of panic disorder such as depression and anxiety. Fluoxetine has only been evaluated in open trials, although these results are generally positive. Paroxetine has shown similar efficacy to clomipramine in a large, controlled study, although the other SSRIs have seldom been investigated. Fluvoxamine lacks the activating properties possessed by some SSRIs and this also makes it a useful candidate for the treatment of anxious depression. The efficacy of fluvoxamine in obsessive-compulsive disorder has been established in several double-blind, placebo-controlled trials. In clinical terms, fluvoxamine is approximately as effective as clomipramine, but with a decidedly better adverse event profile. Fluoxetine has also proved effective in obsessive-compulsive disorder, although a recent meta-analysis suggests that fluvoxamine may be somewhat more effective. The other SSRIs have not been sufficiently well studied to justify conclusive statements.

show abstract

A Double-Blind Comparison of Buspirone, Clobazam, and Placebo in Patients with Anxiety Treated in a General Practice Setting

Cited by 31 publications

References 0 publications

Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients

Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients

Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study on the Pharmacodynamics of ABIO-08/01, a New CNS Drug with Potential Anxiolytic Activity

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review

Contact Info

Product

Resources

About